2009
DOI: 10.1016/s0022-5347(09)61568-8
|View full text |Cite
|
Sign up to set email alerts
|

Further Analyses From the Reduce Prostate Cancer Risk Reduction Trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
22
1

Year Published

2009
2009
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 22 publications
(24 citation statements)
references
References 0 publications
1
22
1
Order By: Relevance
“…In this placebocontrolled, randomised study, conducted in men at increased risk of developing prostate cancer on the basis of an elevated PSA but one negative biopsy, four years of treatment with dutasteride significantly reduced the incidence of prostate cancer, as judged by the numbers of positive second and third biopsies at two and four years respectively. 7 Importantly, and in contrast to previous studies with finasteride, there did not appear to be an increase in the number of highgrade cancers among those treated in the active arm. Time will tell whether this reduction translates into real clinical benefit in terms of…”
Section: Dutasteridecontrasting
confidence: 56%
“…In this placebocontrolled, randomised study, conducted in men at increased risk of developing prostate cancer on the basis of an elevated PSA but one negative biopsy, four years of treatment with dutasteride significantly reduced the incidence of prostate cancer, as judged by the numbers of positive second and third biopsies at two and four years respectively. 7 Importantly, and in contrast to previous studies with finasteride, there did not appear to be an increase in the number of highgrade cancers among those treated in the active arm. Time will tell whether this reduction translates into real clinical benefit in terms of…”
Section: Dutasteridecontrasting
confidence: 56%
“…Two large trials, pcpt (Prostate Cancer Prevention Trial) 30 and reduce (Reduction by Dutasteride of Prostate Cancer Events) 31 have reported that the rate of prostate cancer diagnosis declines by 25%-30% with 5aris. Many men in these studies harboured undiagnosed prostate cancer at entry.…”
Section: Future Advancesmentioning
confidence: 99%
“…4 Eligible men were between ages 50 and 75 years, with a single, negative biopsy (6-12 cores) within 6 months before enrollment in the study and a serum prostate-specific antigen level of 2.5 to 10.0 ng/mL (for men 50-60 years), or 3.0-10.0 ng/mL (for men older than 60 years).…”
Section: Study Populationmentioning
confidence: 99%
“…4 After the trial's initiation, the ISUP 2005 modified Gleason score was introduced. 3 On completion of the trial, biopsies that were positive for prostate cancer were reread by an independent pathologist (M.S.L.)…”
mentioning
confidence: 99%